252 related articles for article (PubMed ID: 33854160)
1. Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues.
Jang TY; Wei YJ; Liu TW; Yeh ML; Liu SF; Hsu CT; Hsu PY; Lin YH; Liang PC; Hsieh MH; Ko YM; Tsai YS; Chen KY; Lin CC; Tsai PC; Wang SC; Huang CI; Lin ZY; Chen SC; Chuang WL; Huang JF; Dai CY; Huang CF; Yu ML
Sci Rep; 2021 Apr; 11(1):8184. PubMed ID: 33854160
[TBL] [Abstract][Full Text] [Related]
2. High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort.
Bockmann JH; Grube M; Hamed V; von Felden J; Landahl J; Wehmeyer M; Giersch K; Hall MT; Murray JM; Dandri M; Lüth S; Lohse AW; Lütgehetmann M; Schulze Zur Wiesch J
BMC Gastroenterol; 2020 Jan; 20(1):24. PubMed ID: 32000689
[TBL] [Abstract][Full Text] [Related]
3. Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues.
Jang TY; Wei YJ; Yeh ML; Liu SF; Hsu CT; Hsu PY; Liu TW; Lin YH; Liang PC; Hsieh MH; Ko YM; Tsai YS; Chen KY; Lin CC; Tsai PC; Wang SC; Huang CI; Lin ZY; Chen SC; Chuang WL; Huang JF; Dai CY; Huang CF; Yu ML
J Formos Med Assoc; 2021 Jan; 120(1 Pt 2):303-310. PubMed ID: 33109431
[TBL] [Abstract][Full Text] [Related]
4. Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy.
Jang TY; Wei YJ; Hsu CT; Hsu PY; Liu TW; Lin YH; Liang PC; Hsieh MH; Ko YM; Tsai YS; Chen KY; Lin CC; Tsai PC; Wang SC; Huang CI; Yeh ML; Lin ZY; Chen SC; Chuang WL; Huang JF; Dai CY; Huang CF; Yu ML
J Gastroenterol Hepatol; 2020 Nov; 35(11):1886-1892. PubMed ID: 32247291
[TBL] [Abstract][Full Text] [Related]
5. Demographics and outcomes of hepatitis B and D: A 10-year retrospective analysis in a Swiss tertiary referral center.
Vieira Barbosa J; Sahli R; Aubert V; Chaouch A; Moradpour D; Fraga M
PLoS One; 2021; 16(4):e0250347. PubMed ID: 33905426
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis D virus infection, cirrhosis and hepatocellular carcinoma in The Gambia.
Mahale P; Aka P; Chen X; Pfeiffer RM; Liu P; Groover S; Mendy M; Njie R; Goedert JJ; Kirk GD; Glenn JS; O'Brien TR
J Viral Hepat; 2019 Jun; 26(6):738-749. PubMed ID: 30661282
[TBL] [Abstract][Full Text] [Related]
7. Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.
Alfaiate D; Clément S; Gomes D; Goossens N; Negro F
J Hepatol; 2020 Sep; 73(3):533-539. PubMed ID: 32151618
[TBL] [Abstract][Full Text] [Related]
8. High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta.
Romeo R; Foglieni B; Casazza G; Spreafico M; Colombo M; Prati D
PLoS One; 2014; 9(3):e92062. PubMed ID: 24658127
[TBL] [Abstract][Full Text] [Related]
9. Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients.
Cho YY; Lee JH; Chang Y; Nam JY; Cho H; Lee DH; Cho EJ; Lee DH; Yu SJ; Lee JM; Kim YJ; Yoon JH
J Viral Hepat; 2018 Oct; 25(10):1161-1171. PubMed ID: 29741286
[TBL] [Abstract][Full Text] [Related]
10. A prominent role of Hepatitis D Virus in liver cancers documented in Central Africa.
Amougou MA; Noah DN; Moundipa PF; Pineau P; Njouom R
BMC Infect Dis; 2016 Nov; 16(1):647. PubMed ID: 27821080
[TBL] [Abstract][Full Text] [Related]
11. A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma.
Ji J; Sundquist K; Sundquist J
J Natl Cancer Inst; 2012 May; 104(10):790-2. PubMed ID: 22423008
[TBL] [Abstract][Full Text] [Related]
12. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk.
Ren P; Cao Z; Mo R; Liu Y; Chen L; Li Z; Zhou T; Lu J; Liu Y; Guo Q; Chen R; Zhou H; Xiang X; Cai W; Wang H; Bao S; Xu Y; Gui H; Xie Q
Expert Opin Biol Ther; 2018 Oct; 18(10):1085-1094. PubMed ID: 30182763
[TBL] [Abstract][Full Text] [Related]
13. On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients.
Huang CF; Jang TY; Jun DW; Ahn SB; An J; Enomoto M; Takahashi H; Ogawa E; Yoon E; Jeong SW; Shim JJ; Jeong JY; Kim SE; Oh H; Kim HS; Cho YK; Kozuka R; Inoue K; Cheung KS; Mak LY; Huang JF; Dai CY; Yuen MF; Nguyen MH; Yu ML
Liver Int; 2022 Jan; 42(1):59-68. PubMed ID: 34687130
[TBL] [Abstract][Full Text] [Related]
14. Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B.
Hsu YC; Wu CY; Lane HY; Chang CY; Tai CM; Tseng CH; Lo GH; Perng DS; Lin JT; Mo LR
J Antimicrob Chemother; 2014 Jul; 69(7):1920-7. PubMed ID: 24576950
[TBL] [Abstract][Full Text] [Related]
15. Magnitude and genotype of hepatitis delta virus among chronic hepatitis B carriers with a spectrum of liver diseases in Ethiopia.
Tassachew Y; Belyhun Y; Abebe T; Mihret A; Teffera T; Ababi G; Shewaye A; Desalegn H; Aseffa A; Mulu A; Howe R; Liebert UG; Maier M
Ann Hepatol; 2023; 28(1):100770. PubMed ID: 36220615
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono infection: A meta-analysis.
Chang TE; Su CW; Huang YS; Huang YH; Hou MC; Wu JC
J Chin Med Assoc; 2022 Jan; 85(1):30-41. PubMed ID: 35006125
[TBL] [Abstract][Full Text] [Related]
17. Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B.
Lee J; Yoo SH; Sohn W; Kim HW; Choi YS; Won JH; Heo JY; Park SJ; Park YM
Clin Mol Hepatol; 2016 Sep; 22(3):339-349. PubMed ID: 27729627
[TBL] [Abstract][Full Text] [Related]
18. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
[TBL] [Abstract][Full Text] [Related]
19. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.
Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY
J Gastroenterol Hepatol; 2019 Feb; 34(2):442-449. PubMed ID: 29968933
[TBL] [Abstract][Full Text] [Related]
20. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study.
Wu CY; Lin JT; Ho HJ; Su CW; Lee TY; Wang SY; Wu C; Wu JC
Gastroenterology; 2014 Jul; 147(1):143-151.e5. PubMed ID: 24704525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
